# OnCo record orca-bio (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/orca-bio/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "orca-bio" ;
  schema:name "Orca Bio"@en ;
  schema:alternateName "Orca Biosystems"@en, "Orca Biosystems, Inc."@en, "orca-biosystems"@en ;
  schema:description "Orca Bio makes precision-engineered versions of donor stem cell transplants for blood cancers, sorting the donor cells so that patients get the cells that fight cancer and rebuild the immune system with fewer of the cells that cause graft versus host disease. Its first product, TREGZI, was approved in the US in June 2026."@en ;
  schema:url <https://onco.cc/companies/orca-bio/>, <https://orcabio.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://orcabio.com/>, <https://orcabio.com/orca-bios-tregzi-receives-u-s-fda-approval-as-first-and-only-precision-engineered-cell-therapy-for-allogeneic-transplant-in-adults-with-hematological-malignanciesorca-bio-adds-east/>, <https://orcabio.com/newsroom/>, <https://www.sec.gov/Archives/edgar/data/1720544/000172054420000002/primary_doc.xml>, <https://clinicaltrials.gov/search?lead=Orca%20Biosystems%2C%20Inc.> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/all-leukemia/>, <https://onco.cc/cancers/mds/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/> ;
  onco:technologies <https://onco.cc/technologies/allogeneic-cell-therapy/> ;
  onco:drugs <https://onco.cc/drugs/tregzi/> ;
  onco:trials <https://onco.cc/trials/nct07216443/> .